All In Biotech

Drug Trial Radar · NCT05382442

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

254

Planned (sponsor's estimate)

Start

Jun 27, 2022

Primary completion

May 15, 2026

Study completion Aug 12, 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
Collaborators
Summit Therapeutics
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • AK112Drug

    AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity

  • AK117Drug

    AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity

  • OxaliplatinDrug

    Oxaliplatin via IV infusion

  • CapecitabineDrug

    Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days

  • IrinotecanDrug

    Irinotecan via IV infusion

  • LeucovorinDrug

    Leucovorin via IV infusion

  • 5-fluorouracilDrug

    5-fluorouracil via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rates (ORR)Time frame: Up to approximately 2 years
  2. Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Summit Therapeutics Research Site

    Los Angeles, California

  • Summit Therapeutics Research Site

    Murrieta, California

  • Summit Therapeutics Research Site

    Fairfax, Virginia

  • The Sixth Hospital,Sun Yat-sen University

    Guanzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.